clinical trial · NCT06533644
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune, Inc.·phase2·recruiting·n = 70
Metastatic Castration-resistant Prostate CancerPartial OncolysisSV-102
brief summary
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
started
May 29, 2025
primary completion
Dec 14, 2027
completion
Dec 14, 2027
last updated
Feb 27, 2026
official title
A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol